Back to search

Article

Third dose vaccine With BNT162b2 and its response on Long COVID after Breakthrough infections

2021-11-09

Abstract excerpt

<h4>Background</h4> Breakthrough events are not rare after emerging of Delta variant. On the other hand, long COVID is an unsolved issue where sufferers suffer a lot. Some study has shown that COVID-19 vaccine has improved some clinical and libratory parameters in long COVID. But what will be the possible measures against long COVID after the breakthrough event is still a burning question. <h4>Method</h4> We have...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
f2de3095-3249-5a9f-9240-577225d2bf6e
DOI
10.1101/2021.11.08.21266037
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Third dose vaccine With BNT162b2 and its response on Long COVID after Breakthrough infectionsDOI 10.1101/2021.11.08.21266037
Third dose vaccine With BNT162b2 and its response on Long COVID after Breakthrough infectionsSemantic proximity
Clinicogenomic analysis of breakthrough infections by SARS CoV2 variants after ChAdOx1 nCoV- 19 vaccination in healthcare workersSemantic proximity
Antibody and T cell responses against wild-type and Omicron SARS-CoV-2 after the third dose of BNT162b2 in healthy adolescentsSemantic proximity
The effectiveness of the first dose of BNT162b2 vaccine in reducing SARS-CoV-2 infection 13-24 days after immunization: real-world evidenceSemantic proximity
Evaluation of COVID-19 vaccine breakthrough infections among immunocompromised patients fully vaccinated with BNT162b2Semantic proximity
Comprehensive genomic, immunological and clinical analysis of COVID-19 vaccine breakthrough infections: a prospective, comparative cohort studySemantic proximity
Viral loads of Delta-variant SARS-CoV2 breakthrough infections following vaccination and booster with the BNT162b2 vaccineSemantic proximity
The Effectiveness of the First Dose of BNT162b2 Vaccine in Reducing SARS-CoV-2 Infection: Real-World EvidenceSemantic proximity
SARS-CoV-2 vaccine Alpha and Delta variant breakthrough infections are rare and mild, but happen relative early after vaccinationSemantic proximity
Immunogenicity and reactogenicity against the SARS-CoV-2 variants following heterologous primary series involving CoronaVac, ChAdox1 nCov-19 and BNT162b2 plus BNT162b2 booster vaccination: An open-label randomized study in healthy Thai adultsSemantic proximity
Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in QatarSemantic proximity
Immune Response and Clinical Outcomes of BNT162b2 and mRNA1273 Fourth Dose COVID-19 Vaccines; Three Months Follow-upSemantic proximity
Select a neighboring publication to make it the new centre.